FindTrial
Sign In

Toca 511 vector

BIOLOGICAL3 trials

Sponsors

Tocagen Inc.

Conditions

Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaAstrocytomaGlioblastomaGlioblastoma MultiformeGliomas, Malignant

Phase 1

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
CompletedNCT01156584
Tocagen Inc.Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +1
Start: 2010-07-31End: 2016-08-18Updated: 2018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
CompletedNCT01470794
Tocagen Inc.Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +1
Start: 2012-02-29End: 2016-04-12Updated: 2018-05-21
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
TerminatedNCT04327011
Tocagen Inc.Astrocytoma, Glioblastoma Multiforme, Gliomas, Malignant
Start: 2011-02-28End: 2019-12-31Updated: 2020-03-30

Related Papers

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Clinical Cancer Research2020-08-1827 citations
ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA
Neuro-Oncology2018-11-011 citations
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
2018-09-01131 citations
Abstract 5630: Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)
Cancer Research2018-07-01
25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2018-06-011 citations
Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Molecular Cancer Therapeutics2018-01-01
Abstract B010: Antitumor cellular immune response elicited by Toca 511 and Toca FC therapy in preclinical and clinical studies
Molecular Cancer Therapeutics2018-01-01
A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.
2017-12-0524 citations
Gene Therapy Shows Promising Efficacy for Recurrent, High-Grade Gliomas
Oncology Times2017-11-10
ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT
Neuro-Oncology2017-11-01
ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL
Neuro-Oncology2017-11-01
Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.
Journal of Clinical Oncology2017-05-201 citations
Abstract B03: Development of retroviral replicating vectors expressing codon-optimized nitroreductase for prodrug activator gene therapy in human glioma models
Clinical Cancer Research2017-01-011 citations
ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL
Neuro-Oncology2016-11-011 citations
GENT-42. SIMULTANEOUS MEASUREMENT OF MGMT METHYLATION AND DETERMINATION OF IDH1 R132H AND CpG ISLAND METHYLATOR PHENOTYPE (CIMP) IN GLIOMAS USING COUPLED ABSCRIPTION PCR SIGNALING (CAPS)
Neuro-Oncology2016-11-01
ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011)
Neuro-Oncology2016-11-01
ATIM-24. SYSTEMATIC IDENTIFICATION OF TOCA 511 RETROVIRUS INTEGRATION SITES AND MUTATION PROFILES IN TUMOR AND BLOOD SAMPLES FROM PATIENTS UNDERGOING INVESTIGATIONAL TREATMENT FOR RECURRENT HIGH GRADE GLIOMA CORRELATES WITH FAVORABLE CLINICAL SAFETY PROFILE
Neuro-Oncology2016-11-01
OS8 - 150 Encouraging Survival with Toca 511 and Toca FC Compared to External Lomustine Control
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2016-10-01
Abstract 3212: Combining Toca 511 and 5-fluorocytosine with αPD-1 or αCTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model
Cancer Research2016-07-15

20 more papers not shown